CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency
Insufficient functional T cell persistence impedes therapeutic success of chimeric antigen receptor (CAR) therapies. Here we performed a CAR-adapted base-editing screen of PIK3CD, a key regulator of T cell function, metabolism and fate. We identified point mutations that beneficially modulate CAR T cell profiles in 4-1BBz and 28z CAR T cells, respectively. We found that point mutations with differing effects on phosphatidylinositol-3-kinase delta (PI3Kδ) signaling activity were advantageous in distinct CAR contexts: The PI3Kδ-activating substitution E81K enhanced proliferation, metabolic fitness and effector function of 4-1BBz CARs, promoting long-term functional persistence and enhanced therapeutic efficacy in vivo. Conversely, the PI3Kδ-attenuating substitution L32P improved T cell memory formation and functionality of 28z CAR T cells. Together, our approach of rational optimization of activation-dependent signaling through targeted allelic reprogramming (ROADSTAR) illustrates the importance of CAR design-specific fine-tuning of intrinsic T cell signaling and demonstrates the potential of base editing for next-generation cellular therapies.
Authors
- Celina May
- Priv.Doz.Dr. Leticia Quintanilla-Martinez
- Denis Andrei Ispan
- Manfred Claassen (ORCID: https://orcid.org/0000-0002-4583-9083)
- Judith Feucht (ORCID: https://orcid.org/0000-0002-8745-1079)
- Carolin Schneider (ORCID: https://orcid.org/0000-0001-8936-2793)
- Meike Thiemann
- Hannah Wurzer (ORCID: https://orcid.org/0000-0001-5816-1286)
- Christoph Trautwein (ORCID: https://orcid.org/0000-0003-4672-6395)
- Mara Mitstorfer
- Michel Sadelain (ORCID: https://orcid.org/0000-0002-9031-8025)
- Katrin Bartels
- Yu-Jui Ho (ORCID: https://orcid.org/0000-0002-7540-024X)
- Jan Schleicher (ORCID: https://orcid.org/0000-0002-2568-8302)
- Nadine Brückner (ORCID: https://orcid.org/0009-0008-4658-3279)
- Irene González-Menéndez (ORCID: https://orcid.org/0000-0003-3608-4704)
- Jiangqing Chen
- Mary Rausch
- Philip Bucher (ORCID: https://orcid.org/0000-0001-7951-1580)
- Josef Leibold (ORCID: https://orcid.org/0000-0003-2336-1987)
- Nayan Jain (ORCID: https://orcid.org/0000-0002-3831-2136)
- Melanie Grimm
- Jule Kortendieck
- Steffen Hardy
- Francisco J. Sánchez-Rivera
- Dennis Letzgus
- Jie Sun
- Julia Quach
- Bettina Weigelin
Institutions
- Siemens (Germany) (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Columbia University Irving Medical Center (US)
- Universitätsklinikum Tübingen (DE)
- Research Institute for Work, Technology and Culture (DE)
- University Children's Hospital Tübingen (DE)
- First Affiliated Hospital Zhejiang University (CN)
- Massachusetts Institute of Technology (US)
- Zhejiang University (CN)
- Columbia University (US)
- University of Tübingen (DE)
Publication Details
- Journal
- Nature Cancer
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1038/s43018-025-01099-7
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 24.20